BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on BridgeBio Pharma. The associated price target remains the same with $95.00.

Tyler Van Buren has given his Buy rating due to a combination of factors tied to BridgeBio’s strong commercial and clinical execution. He points to the robust launch of Attruby, where quarterly and full-year sales have exceeded expectations, and prescription trends show accelerating uptake across a broad base of prescribers, supporting a sustained growth profile into 2026.

He also emphasizes that three successful Phase III programs and multiple planned NDA filings through 2026 create several potential blockbuster drivers that can transform the company’s earnings power. In his view, this pipeline, combined with rising Attruby revenues, positions BridgeBio to turn cash-flow positive by late 2027 and evolve into a durable cash generator from 2028 onward, justifying a Buy recommendation on the shares.

Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and BridgeBio Pharma. According to TipRanks, Van Buren has an average return of 21.7% and a 55.14% success rate on recommended stocks.

In another report released on February 18, Bank of America Securities also maintained a Buy rating on the stock with a $97.00 price target.